Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Pulmonary drug delivery route is used to inhale medication through the respiratory tract. The medication reaches the blood stream through the alveolar surface of the lungs. Pulmonary route of drug administration is mainly used in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
The global pulmonary drug delivery systems market is estimated to account for US$ 30,005.80 Mn in terms of value in 2020 and is expected to reach US$ 41,072.7 Mn by the end of 2027.
Global Pulmonary Drug Delivery Systems Market: Drivers
Increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel growth of the global pulmonary drug delivery systems market over the forecast period. For instance, according to the study ‘Chronic Obstructive Pulmonary Disease in Latin America’, published in January 2019 in the journal Annals of Global Health, the prevalence of COPD in Latin American cities ranged between 6.2 and 19.6% in individuals aged 40 years and above.
Moreover, advantages associated with pulmonary drug delivery route are also expected to aid in growth of the market. These advantages include, ease of administration, requires low amount of drug compared to that in oral dosage, very less or negligible side effect, quick onset of action, drug degradation by liver is avoided, targeted drug delivery, and larger absorption area for lungs.
MDIs held dominant position in the global pulmonary drug delivery systems market in 2019, accounting for 53.9% share in terms of value, followed by DPIs and nebulizers, respectively
Figure 1. Global Pulmonary Drug Delivery Systems Market Share (%), by Value, by Product Type, 2019
Global Pulmonary Drug Delivery Systems Market: Restraints
Stringent regulatory scenario is expected to hinder growth of the market. Regulatory requirements for pulmonary drug delivery systems are quite challenging as MDIs and DPIs are considered as drug-device combination products, and therefore, are regulated under new provisions by the drug regulatory authorities due to the following factors:
- Product performance is the combination of individual function of both device and drug formulation
- Product operating technique may affect the dose administration
- Product manufacturing and use have significant impact on environment
Moreover, various mechanical, chemical, and immunological barriers along with behavioral barriers of poor adherence and poor inhaler technique also limit growth of the market.
Pulmonary Drug Delivery Systems Market Report Coverage
||Market Size in 2019:
||US$ 28,700.0 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 41,072.7 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Product Type: Nebulizers, MDIs, DPIs.
- By Application: Asthma, COPD, Cystic Fibrosis.
3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare
- Product Launches
- Technological Advancement
|Restraints & Challenges:
- Stringent Regulations
- Patent Losses
Global Pulmonary Drug Delivery Systems Market: Opportunities
R&D in dry powder inhalation is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, in June 2020, researchers from University of Szeged, Hungary, reported development of a carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application.
Moreover, adoption of vibrating mesh nebulizers for emerging therapeutics is expected to ensure adequate aerosol drug delivery, thereby aiding in growth of the market.
The global pulmonary drug delivery systems market was valued at US$ 28,700.0 Mn in 2019 and is forecast to reach a value of US$ 41,072.7 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.
Figure 2. Global Pulmonary Drug Delivery Systems Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Major players in the market are focused on adopting various marketing strategies to enhance their market share. For instance, in December 2019, Glenmark Pharmaceuticals Ltd. secured National Pharmaceutical Pricing Authority’s (India) nod for separate price for its digital dose inhaler or ‘Digihaler’.
Launch of devices to track usage of MDIs is boosting growth of the market. For instance, in November 2019, Lupin Ltd. launched a device – Adhero – to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.
Global Pulmonary Drug Delivery Systems Market: Competitive Landscape
Major players operating in the global pulmonary drug delivery systems market include, 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Philips Healthcare.
Global Pulmonary Drug Delivery Systems Market: Key Developments
Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, in April 2019, Glenmark Pharmaceuticals Ltd. launched two new steroid inhalers that include Soprobec (beclometasone), a metered-dose aerosol inhaler, and Stalpex (salmeterol/fluticasone), a breath-actuated inhaler.